Anti-inflammatory Bowel Disease Agent
PREGNANCY RECOMMENDATION: Compatible
BREASTFEEDING RECOMMENDATION: Limited Human Data—Potential Toxicity
PREGNANCY SUMMARY
The maternal benefits of therapy with mesalamine appear to outweigh the potential risks to the fetus. No teratogenic effects due to mesalamine have been described and, although toxicity in the fetus has been reported in one case, a causal relationship between the drug and the outcome is controversial.
FETAL RISK SUMMARY
Mesalamine (5-aminosalicylic acid, 5-ASA) is administered by either rectal suspension or suppository for the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. It also results from metabolism in the large intestine of the oral preparation sulfasalazine, which is split to mesalamine and sulfapyridine, and from balsalazide and olsalazine, oral formulations that are metabolized in the colon to mesalamine. The history, pharmacology, and pharmacokinetics of mesalamine and olsalazine were extensively reviewed in a 1992 reference (1).
Reproduction studies in rats and rabbits at oral doses of 480 mg/kg/day observed no fetal toxicity or teratogenicity (2).
Sulfasalazine and one of the metabolites, sulfapyridine, readily cross the placenta and could displace bilirubin from albumin if the concentrations were great enough. Mesalamine is bound to different sites on albumin than bilirubin and, thus, has no bilirubin-displacing ability (3). Moreover, only small amounts of mesalamine are absorbed from the cecum and colon into the systemic circulation, and most of this is rapidly excreted in the urine (4).
A 1987 reference reported the concentrations of mesalamine and its metabolite, acetyl-5-aminosalicylic acid, in amniotic fluid at 16 weeks’ gestation and in maternal and cord plasma at term in women treated prophylactically with sulfasalazine 3 g/day (5). The drug and metabolite levels (all in mcg/mL) and the number of patients were as follows: amniotic fluid (N = 4), 0.02–0.08 and 0.07–0.77, respectively; maternal plasma (N = 5), 0.08–0.29 and 0.31–1.27, respectively; and cord plasma (N = 5), <0.02–0.10 and 0.29–1.80, respectively. No effects on the fetus or newborn from the maternal drug therapy were mentioned. At delivery in a woman taking 1 g of mesalamine 3 times daily, the concentrations of the drug and its metabolite, 3.3 hours after the last dose, in the mother’s serum were 1.2 and 2.8 mcg/mL, respectively, and in the umbilical cord serum 0.4 and 5.7 mcg/mL, respectively (6). The cord:maternal serum ratios were 0.33 and 2.0, respectively.
A review of drug therapy for ulcerative colitis recommended that women taking mesalamine to maintain remission of the disease should continue the drug when trying to conceive or when pregnant (7). A study published in 1993 described the course of 19 pregnancies in 17 women (ulcerative colitis N = 10; Crohn’s disease N = 7) who received mesalamine (mean dose 1.7 g/day; range 0.8–2.4 g/day) throughout gestation (8). Full-term deliveries occurred in 18, and 1 patient, with a history of 4 previous miscarriages, suffered a spontaneous abortion. No congenital malformations were observed.
Only one report has described possible in utero mesalamine-induced toxicity that may have occurred during 2nd trimester exposure to the drug (9). The 24-year-old mother was treated, between the 13th and 24th week of gestation, for Crohn’s disease with 4 g/day of mesalamine for 5 weeks, then tapered to 2 g/day for 6 weeks, then stopped. A fetal ultrasound at 17 weeks’ gestation was normal, but a second examination at 21 weeks’ showed bilateral renal hyperechogenicity (9). The term male infant had a serum creatinine at birth of 115 µmol/L (normal 18–35 µmol/L). Renal hyperechogenicity was confirmed at various times up to 6 months of age. At this age, the serum creatinine was 62 µmol/L with a creatinine clearance of 52 mL/min (normal 80–90 mL/min). A renal biopsy at 6 months of age showed focal tubulointerstitial lesions with interstitial fibrosis and tubular atrophy in the absence of cell infiltration (9). Because no other cause of the renal lesions could be found and there was some resemblance to lesions induced by the prostaglandin synthesis inhibitor, indomethacin, the authors attributed the defect to mesalamine (9). A letter published in response to this study, however, questioned the association between the drug and observed renal defect because of the lack of toxicity in an unpublished series of 60 exposed pregnancies and the lack of evidence that mesalamine causes renal prostaglandin synthesis inhibition in utero (10).
A 1997 report described the successful outcomes of 19 pregnancies followed prospectively in 16 women with proven distal colitis (11). The women received either 4-g mesalamine enemas 3 times weekly or a 500-mg mesalamine suppository every night throughout gestation. No fetal abnormalities were observed during pregnancy and all of the full-term offspring were normal at birth and at a median follow-up of 2 years (range 2 months to 5 years) (11).
A 1998 prospective study reported the pregnancy outcomes of 165 women exposed to mesalamine (146 during the 1st trimester) who had contacted a teratogen information service (TIS) (12). The study patients were compared with 165 matched controls who had called the TIS concerning nonteratogenic exposures. There were no significant differences between the two groups in spontaneous abortions (6.7% vs. 8.5%), ectopic pregnancies (0.6% vs. 0%), or elective abortions (none were associated with malformed fetuses) (4.2% vs. 1.8%). There was one major defect (an extra right thumb) in the study group compared with five major anomalies in controls (ns). Eight subjects had minor malformations compared with five controls (ns). However, compared with controls, significantly more preterm deliveries occurred in subjects (13.0% vs. 4.7%), the mean birth weight was lower (3253 vs. 3461 g), and the mean maternal weight gain was lower (13.1 vs. 15.6 kg) (12).
A 2004 report described the pregnancy outcomes of 113 women who were being treated for inflammatory bowel disease (39 ulcerative colitis; 73 Crohn’s disease; and 1 indeterminate colitis) (13). In the group, there were 207 pregnancies, 100 during treatment with a 5-ASA agent (mesalamine, sulfasalazine, balsalazide, or olsalazine) at sometime during pregnancy. Other agents used included 49 cases with prednisone, 101 with azathioprine or mercaptopurine, 27 with metronidazole, 18 with ciprofloxacin, and 2 with cyclosporine. The pregnancy outcomes of the first eligible pregnancy in the 113 women were 2 ectopic pregnancies, 2 elective abortions, 16 spontaneous abortions, 6 premature infants, 85 full-term infants (1 set of twins), and 3 major defects (2.7%). However, one of the “defects” was a case of immature lungs, which is not considered a congenital defect. The other two defects were imperforate anus and an unspecified heart defect. In addition, the two elective abortions were for unspecified fetal defects. The study concluded that there was no evidence that any of the drugs used either alone or in combination was associated with poor pregnancy outcomes (13).
A 2012 case described a 27-year-old woman with ulcerative colitis who was treated throughout pregnancy with allopurinol 100 mg/day, mercaptopurine 25 mg/day, and mesalazine 4 g/day (14). Pregnancy was complicated by diarrhea and blood loss in the 2nd trimester. An elective cesarean section was performed at 39 weeks to give birth to a healthy 3550-g infant (sex not specified) with Apgar score of 9, 10, and 10 at 1, 5, and 10 minutes, respectively. No anomalies were observed in the infant (14).
In contrast to sulfasalazine, mesalamine apparently has no adverse effect on spermatogenesis. Treatment of males with sulfasalazine may adversely affect spermatogenesis (15–19), but either stopping therapy or changing to mesalamine allows recovery of sperm production, usually within 3 months (16–19).
BREASTFEEDING SUMMARY
Small amounts of mesalamine are excreted into human milk. A 1990 report described the excretion of mesalamine and its metabolite, acetyl-5-aminosalicylic acid, into breast milk (20). The woman was receiving 500 mg 3 times daily for ulcerative colitis. In a single plasma and milk sample obtained 5.25 hours after a dose, milk and plasma levels of mesalamine were 0.11 and 0.41 mcg/mL, respectively, a milk:plasma ratio of 0.27. Milk and plasma levels of acetyl-5-aminosalicylic acid were 12.4 and 2.44 mcg/mL, respectively, a ratio of 5.1. In another study, women treated prophylactically with 3 g/day of sulfasalazine had milk levels of mesalamine and acetyl-5-aminosalicylic acid of 0.02 and 1.13–3.44 mcg/mL, respectively (5). No adverse effects on the nursing infants were mentioned.
Low concentrations of mesalamine and its metabolite were also found in a woman taking 1 g 3 times daily (6). Maternal serum levels of the drug and metabolite, determined at 7 and 11 days postpartum, were 0.6 and 1.1 mcg/mL (day 7) and 1.1 and 1.8 mcg/mL (day 11), respectively. Milk concentrations of the drug and metabolite at these times were 0.1 and 18.1 mcg/mL (day 7) and 0.1 and 12.3 mcg/mL (day 11), respectively, representing milk:plasma ratios for mesalamine of 0.17 and 0.09 (day 7 and 11), respectively, and for the metabolite of 16.5 and 6.8 (day 7 and 11), respectively. The estimated daily intake by the infant of mesalamine and metabolite was 0.065 mg (0.015 mg/kg) and 10 mg (2.3 mg/kg), respectively, considered to be negligible amounts (6).
A study published in 1993 described the excretion of olsalazine, a prodrug that is partially (2.4%) absorbed into the systemic circulation before conversion of the remainder by colonic bacteria into two molecules of mesalamine (see Olsalazine), in the breast milk of a woman 4 months postpartum (21). Following a 500-mg oral dose, olsalazine, olsalazine sulfate, and mesalamine were undetectable in breast milk up to 48 hours (detection limits 0.5, 0.2, and 1.0 µmol/L, respectively). Acetyl-5-aminosalicylic concentrations at 10, 14, and 24 hours, were 0.8, 0.86, and 1.24 µmol/L, respectively, but undetectable (detection limit 1.0 µmol/L) during the first 6 hours and after 24 hours. The quantities detected were considered clinically insignificant (21).
Diarrhea in a nursing infant, apparently because of the rectal administration of mesalamine to the mother, has been reported (22). The mother had relapsing ulcerative proctitis. Six weeks after childbirth, treatment was begun with 500-mg mesalamine suppositories twice daily. Her exclusively breastfed infant developed watery diarrhea 12 hours after the mother’s first dose. After 2 days of therapy, the mother stopped the suppositories and the infant’s diarrhea stopped 10 hours later. Therapy was reinstituted on four occasions with diarrhea developing each time in the infant 8–12 hours after the mother’s first dose and stopping 8–12 hours after therapy was halted. Because of the severity of the mother’s disease, breastfeeding was discontinued and no further episodes of diarrhea were observed in the infant (22).
Because of the adverse effect described above, a possible allergic reaction, nursing infants of women being treated with mesalamine or olsalazine should be closely observed for changes in stool consistency. The American Academy of Pediatrics classifies 5-aminosalicylic acid (i.e., mesalamine) as a drug that has produced adverse effects in a nursing infant and should be used with caution during breastfeeding (23).
References
1.Segars LW, Gales BJ. Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease. Clin Pharm 1992;11:514–28.
2.Product information. Asacol. Procter & Gamble Pharmaceuticals, 2000.
3.Jarnerot G, Andersen S, Esbjorner E, Sandstrom B, Brodersen R. Albumin reserve for binding of bilirubin in maternal and cord serum under treatment with sulphasalazine. Scand J Gastroenterol 1981;16:1049–55.
4.Berlin CM Jr, Yaffe SJ. Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk. Dev Pharmacol Ther 1980;1:31–9.
5.Christensen LA, Rasmussen SN, Hansen SH, Bondesen S, Hvidberg EF. Salazosulfapyridine and metabolites in fetal and maternal body fluids with special reference to 5-aminosalicylic acid. Acta Obstet Gynecol Scand 1987;66:433–435.
6.Klotz U, Harings-Kaim A. Negligible excretion of 5-aminosalicylic acid in breast milk. Lancet 1993;342:618–9.
7.Kamm MA, Senapati A. Drug management of ulcerative colitis. Br Med J 1992;305:35–8.
8.Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology 1993;105:1057–60.
9.Colombel J-F, Brabant G, Gubler M-C, Locquet A, Comes M-C, Dehennault M, Delcroix M. Renal insufficiency in infant: side-effect of prenatal exposure to mesalazine? Lancet 1994;344:620–1.
10.Marteau P, Devaux CB. Mesalazine during pregnancy. Lancet 1994;344:1708–9.
11.Bell CM, Habal FM. Safety of topical 5-aminosalicylic acid in pregnancy. Am J Gastroenterol 1997;92:2201–2.
12.Diav-Citrin O, Park Y-H, Veerasuntharam G, Polachek H, Bologa M, Pastuszak A, Koren G. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998;114:23–8.
13.Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, Present DH. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 2004;99:656–61.
14.Seinen ML, de Boer NKH, van Hoorn ME, van Bodegraven AA, Bouma G. Safe use of allopurinol and low-dose mercaptopurine therapy during pregnancy in an ulcerative colitis patient. Inflamm Bowel Dis 2013;19:E37.
15.Freeman JG, Reece VAC, Venables CW. Sulphasalazine and spermatogenesis. Digestion 1982;23:68–71.
16.Toovey S, Hudson E, Hendry WF, Levi AJ. Sulphasalazine and male infertility: reversibility and possible mechanism. Gut 1981;22:445–51.
17.O’Morain C, Smethurst P, Dore CJ, Levi AJ. Reversible male infertility due to sulphasalazine: studies in man and rat. Gut 1984;25:1078–84.
18.Chatzinoff M, Guarino JM, Corson SL, Batzer FR, Friedman LS. Sulfasalazine-induced abnormal sperm penetration assay reversed on changing to 5-aminosalicylic acid enemas. Dig Dis Sci 1988;33:108–10.
19.Delaere KP, Strijbos WE, Meuleman EJ. Sulphasalazine-induced reversible male infertility. Acta Urol Belg 1989;57:29–33.
20.Jenss H, Weber P, Hartmann F. 5-Aminosalicylic acid and its metabolite in breast milk during lactation. Am J Gastroenterol 1990;85:331.
21.Miller LG, Hopkinson JM, Motil KJ, Corboy JE, Andersson S. Disposition of olsalazine and metabolites in breast milk. J Clin Pharmacol 1993;33:703–6.
22.Nelis GF. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet 1989;1:383.
23.Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776–89.